# Alkermes plc (ALKS) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/ALKS
## Company Profile
- Ticker: ALKS
- Exchange: NASDAQ
- Sector: Biopharma
- Location: Ireland
- Tags: CNS
## Stock Data
- Close: 41.65 USD
- Market cap: 6887044345.24 USD
- Last updated: 2026-10-06
## Business Overview
Alkermes is a biopharmaceutical company focused on neuroscience, addiction medicine, and specialty therapeutics. Its portfolio combines commercial products and development programs across CNS and related areas.
## Why The Stock Is Moving

As of Oct 6, 2026, ALKS closed down 2.60% at $41.65. No new same-company headline was identified in the current news window.

## Geographic Base

Alkermes is headquartered in Ireland and listed on NASDAQ. It has a global footprint with a strong U.S. commercial base.

## Business Model

The company generates value through product sales, neuroscience development, and lifecycle management across a specialty portfolio. Investors watch commercial execution, pipeline progress, and strategic allocation.

## Landscape Position

Alkermes sits in the upper tier of specialty neuroscience biotech. It is more durable than a pure development-stage name, but catalyst events still matter to the story.

## Future Catalysts

- Alkermes’ catalysts are VIVITROL, Lybalvi, and any CNS pipeline update that broadens the company’s growth mix. Investors will watch whether the commercial base stays durable.

## Recent News
- 2026-09-21 11:00 EST — [Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)](https://biopharmsignal.com/news/ALKS/alkermes-announces-positive-phase-1b-results-demonstrating-clinical-proof-of-con-c7c4d666) — Source: Alkermes plc
- 2026-09-16 11:00 EST — [Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors](https://biopharmsignal.com/news/ALKS/alkermes-announces-appointment-of-anne-c-whitaker-to-board-of-directors-b3a9c263) — Source: Alkermes plc
- 2026-09-10 11:00 EST — [Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards® Program](https://biopharmsignal.com/news/ALKS/alkermes-announces-launch-of-9th-annual-alkermes-pathways-research-awards-progra-a75cef8e) — Source: Alkermes plc
- 2026-08-24 22:30 EST — [The Lancet Neurology Publishes Data From Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1](https://biopharmsignal.com/news/ALKS/the-lancet-neurology-publishes-data-from-alkermes-positive-vibrance-1-phase-2-st-e6ead46b) — Source: Alkermes plc
- 2026-07-28 11:00 EST — [Alkermes plc Reports Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/ALKS/alkermes-plc-reports-second-quarter-2026-financial-results-c2d63966) — Source: Alkermes plc